All research presented at ACG 2025 is strictly embargoed until 12:00 pm local Arizona Time, which aligns with Pacific Daylight Time (PDT)/3:00 pm ET on Sunday, October 26, 2025.
Oral 66 – Duvakitug, an anti-TL1a mAb, Demonstrates Efficacy and Favorable Safety as an Induction Treatment in Adults With Moderately to Severely Active Crohn’s Disease: Results From the RELIEVE UCCD Phase 2b Basket Trial
Wednesday, October 29, 2025 | 8:40 AM – 8:50 AM PDT | North Ballroom 120BC
Author Insight from Vipul Jairath, MBChB, DPhil, MRCP
What’s new here and important for clinicians?
Duvakitug is an anti-TL1A monoclonal antibody, a new therapeutic class being investigated for ulcerative colitis and Crohn’s disease.
The RELIEVE UCCD dose-range finding study was the first placebo-controlled trial of an anti-TL1A antibody in patients with Crohn’s disease. The primary induction results showed that 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (as measured by SES-CD) compared to 13% on placebo, resulting in placebo-adjusted rates of 13% (450 mg) and 35% (900 mg) at week 14. Additionally, the treatment response with duvakitug was observed irrespective of prior advanced therapy exposure.
The endoscopic response rates seen in this study as well as the treatment responses observed across additional clinical and endoscopic endpoints support the potential of duvakitug as an effective new option for patients with moderately to severely active Crohn’s disease.
What do patients need to know?
Healthcare professionals and the scientific community understand the challenges and burdens people living with IBD face. Like many immune-mediated diseases, there is no cure for IBD. While there are several therapies available, not all are always effective for every patient, or sometimes they may diminish in effectiveness overtime or cannot be taken anymore due to side effects. New options that provide a higher and more durable remission rates while controlling symptoms and providing relief are needed.
One area of growing focus in IBD research is TL1A, a cytokine (or protein) that plays a role in a person’s immune response. The TL1A pathway acts like an amplifier for inflammation in the body, typically to help protect the body from foreign threats. When overactive, it boosts certain immune cells, including those implicated in IBD, which results in patients experiencing chronic inflammation and its associated symptoms.
Together, the understanding of the TL1A pathway in IBD and the data in this abstract supports further development and evaluation of duvakitug as a potential treatment option for patients with Crohn’s disease. Duvakitug is not yet approved and is currently under clinical investigation.
Author Contact
Vipul Jairath, MBChB, DPhil, MRCP
Department of Medicine and Department of Epidemiology and Biostatistics, Western University
London, ON, Canada
vjairath [at] uwo.ca
For assistance contacting other ACG experts, please contact Becky Abel, ACG’s Senior Communications Manager, at mediaonly [at] gi.org.